Enzalutamide is under clinical development by Pfizer and currently in Phase II for Adenocarcinoma. According to GlobalData, Phase II drugs for Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Enzalutamide LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Enzalutamide overview

Enzalutamide (Xtandi) is a phenylimidazolidine derivative, acts as anti neoplastic agent. It is formulated as liquid-filled soft gelatin capsules and tablets for oral route of administration. It is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel, indicated for the treatment of metastatic prostate cancer. It is also indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).

Enzalutamide is under development for the treatment of non-metastatic castration-resistant prostate cancer, prostate cancer in patients with non-metastatic biochemical recurrence in the EU, China and Asia, and also for metastatic hormone-sensitive prostate cancer in the U.S, EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation. It is also under development for the treatment of androgen receptor positive (AR+) ovarian, epithelial ovarian cancer, primary peritoneal or fallopian tube cancer (following one, two and three prior therapies),  and pancreatic cancer. It is also under development for refractory/relapsed acute myeloid leukemia, multiple myeloma, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome, primary myelofibrosis, Hodgkin and Non-Hodgkin's lymphoma, 

It was also under development for metastatic castration-resistant prostate cancer in Japan as a first line therapy and HER2 positive triple negative breast cancer in the U.S., EU, Japan and Asia-Pacific and hepatocellular carcinoma in the U.S, EU and Asia. It was also under development for spindle cell squamous cell carcinoma and HER2 positive breast cancer as a second line therapy and androgen receptor positive salivary cancer and COVID-19.

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of Enzalutamide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.